Literature DB >> 10708482

Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation.

X J Wang1, D A Greenhalgh, D R Roop.   

Abstract

Previously, transgenic mice were generated that overexpressed v-Ha-ras or human transforming growth factor alpha (TGFalpha) exclusively in the epidermis, by means of a targeting vector based on the human keratin 1 gene (HK1). Both transgenics exhibited a similar neonatal phenotype of epidermal hyperplasia/hyperkeratosis and, in adults, spontaneous and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced papilloma formation. To assess the synergism in vivo between Ha-ras and TGFalpha, mating experiments were performed. All ras/TGFalpha double genotype progeny (HK1 less than, with dotras/alpha) exhibited an increased epidermal hyperplasia/hyperkeratosis in neonates and accelerated spontaneous papillomatogenesis, compared with single transgenic siblings. HK1 less than, with dotras/alpha mice from the mild lines of HK1 less than, with dotrasxHK1 less than, with dotTGFalpha developed spontaneous papillomas that were not shown in either their parental mice or single transgenic littermates. Unlika in parental or single-genotype siblings, in which TPA promotion-elicited papillomas remained benign, TPA promotion elicited autonomous papillomas in HK1 less than, with dotras/alpha mice and exhibited a novel susceptibility to malignant conversion. Sequence analysis of the endogenous c-Ha-ras from spontaneous and TPA-induced HK1 less than, with dotras/alpha papillomas revealed wild-type sequence. However, carcinomas exhibited c-Ha-ras mutations at codon 61. All tumors analyzed to date expressed wild-type p53. These data provide in vivo evidence that Ha-ras and TGFalpha cooperate in the induction of epidermal hyperplasia and spontaneous tumor formation and predispose to malignant conversion via endogenous c-Ha-ras activation. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708482

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  IGF-I stimulates proliferation of spontaneously immortalized human keratinocytes (HACAT) by autocrine/paracrine mechanisms.

Authors:  G Pozzi; M Guidi; F Laudicina; M Marazzi; L Falcone; R Betti; C Crosti; E E Müller; G E DiMattia; V Locatelli; A Torsello
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

2.  Defining the origins of Ras/p53-mediated squamous cell carcinoma.

Authors:  Andrew C White; Kathy Tran; Joan Khuu; Christine Dang; Yongyan Cui; Scott W Binder; William E Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

3.  RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis.

Authors:  Courtney T Luke; Carolyn E Oki-Idouchi; J Mark Cline; Patricia S Lorenzo
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

4.  IKKalpha is required to maintain skin homeostasis and prevent skin cancer.

Authors:  Bigang Liu; Xiaojun Xia; Feng Zhu; Eunmi Park; Steve Carbajal; Kaoru Kiguchi; John DiGiovanni; Susan M Fischer; Yinling Hu
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743

Review 5.  Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology.

Authors:  Marlon R Schneider; Sabine Werner; Ralf Paus; Eckhard Wolf
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

6.  A tale of terminal differentiation: IKKalpha, the master keratinocyte regulator.

Authors:  Bigang Liu; Feng Zhu; Xiaojun Xia; Eumni Park; Yinling Hu
Journal:  Cell Cycle       Date:  2009-02-10       Impact factor: 4.534

7.  A novel role of RASSF9 in maintaining epidermal homeostasis.

Authors:  Chiou-Mei Lee; Polung Yang; Lih-Chyang Chen; Chia-Chun Chen; Shinn-Chih Wu; Hsiao-Yun Cheng; Yu-Sun Chang
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.